These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 28118029)

  • 1. Cytotoxic Effects of the Therapeutic Radionuclide Rhenium-188 Combined with Taxanes in Human Prostate Carcinoma Cell Lines.
    Lange R; ter Heine R; van Wieringen WN; Tromp AM; Paap M; Bloemendal HJ; de Klerk JM; Hendrikse NH; Geldof AA
    Cancer Biother Radiopharm; 2017 Feb; 32(1):16-23. PubMed ID: 28118029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial).
    van Dodewaard-de Jong JM; de Klerk JM; Bloemendal HJ; van Bezooijen BP; de Haas MJ; Wilson RH; O'Sullivan JM
    Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):1990-8. PubMed ID: 21792569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bench to bedside development of GMP grade Rhenium-188-HEDP, a radiopharmaceutical for targeted treatment of painful bone metastases.
    ter Heine R; Lange R; Breukels OB; Bloemendal HJ; Rummenie RG; Wakker AM; de Graaf H; Beekman FJ; van der Westerlaken MM; Malingré MM; Wielders JP; van den Berg L; Hendrikse NH; de Klerk JM
    Int J Pharm; 2014 Apr; 465(1-2):317-24. PubMed ID: 24560635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study.
    Lange R; Overbeek F; de Klerk JM; Pasker-de Jong PC; van den Berk AM; Ter Heine R; Rodenburg CJ; Kooistra A; Hendrikse NH; Bloemendal HJ
    Nuklearmedizin; 2016 Sep; 55(5):188-95. PubMed ID: 27443809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study.
    Lam MG; Bosma TB; van Rijk PP; Zonnenberg BA
    Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1425-33. PubMed ID: 19319526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative bone single-photon emission computed tomography for prediction of pain relief in metastatic bone disease treated with rhenium-186 etidronate.
    Israel O; Keidar Z; Rubinov R; Iosilevski G; Frenkel A; Kuten A; Betman L; Kolodny GM; Yarnitsky D; Front D
    J Clin Oncol; 2000 Jul; 18(14):2747-54. PubMed ID: 10894875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer.
    Maxon HR; Schroder LE; Thomas SR; Hertzberg VS; Deutsch EA; Scher HI; Samaratunga RC; Libson KF; Williams CC; Moulton JS
    Radiology; 1990 Jul; 176(1):155-9. PubMed ID: 1693784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination 186Re-HEDP and cisplatin supra-additive treatment effects in prostate cancer cells.
    Geldof AA; de Rooij L; Versteegh RT; Newling DW; Teule GJ
    J Nucl Med; 1999 Apr; 40(4):667-71. PubMed ID: 10210227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone.
    O'Sullivan JM; Norman AR; McCready VR; Flux G; Buffa FM; Johnson B; Coffey J; Cook G; Treleaven J; Horwich A; Huddart RA; Parker CC; Dearnaley DP
    Eur J Nucl Med Mol Imaging; 2006 Sep; 33(9):1055-61. PubMed ID: 16572306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
    Palmedo H; Manka-Waluch A; Albers P; Schmidt-Wolf IG; Reinhardt M; Ezziddin S; Joe A; Roedel R; Fimmers R; Knapp FF; Guhlke S; Biersack HJ
    J Clin Oncol; 2003 Aug; 21(15):2869-75. PubMed ID: 12885803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 186Re-HEDP for metastatic bone pain in breast cancer patients.
    Lam MG; de Klerk JM; van Rijk PP
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S162-70. PubMed ID: 15118846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain].
    Róka R; Séra T; Pajor L; Thurzó L; Láng J; Csernay L; Pávics L
    Orv Hetil; 2000 May; 141(19):1019-23. PubMed ID: 10846424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.
    De Klerk JM; Zonnenberg BA; Blijham GH; Van Het Schip AD; Hoekstra A; Han SH; Quirijnen JM; Van Dijk A; Van Rijk PP
    Anticancer Res; 1997; 17(3B):1773-7. PubMed ID: 9179233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study.
    Han SH; de Klerk JM; Tan S; van het Schip AD; Derksen BH; van Dijk A; Kruitwagen CL; Blijham GH; van Rijk PP; Zonnenberg BA
    J Nucl Med; 2002 Sep; 43(9):1150-6. PubMed ID: 12215552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remission of bone metastases after combined chemotherapy and radionuclide therapy with Re-186 HEDP.
    Palmedo H; Grünwald F; Wagner U; Köhler S; Krebs D; Biersack HJ
    Clin Nucl Med; 1998 Aug; 23(8):501-4. PubMed ID: 9712380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer.
    Buffa FM; Flux GD; Guy MJ; O'Sullivan JM; McCready VR; Chittenden SJ; Dearnaley DP
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1114-24. PubMed ID: 12761596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introduction of a new semi-quantitative index with predictive implications in patients with painful osseous metastases after (186)Re-HEDP therapy.
    Zafeirakis A; Zissimopoulos A; Baziotis N; Limouris GS
    Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):91-102. PubMed ID: 21068716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases.
    Han SH; De Klerk JM; Zonnenberg BA; Tan S; Van Rijk PP
    Q J Nucl Med; 2001 Mar; 45(1):84-90. PubMed ID: 11456380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential use of 99mTc-MDP bone scans to plan high-activity 186Re-HEDP targeted therapy of bony metastases from prostate cancer.
    Binnie D; Divoli A; McCready VR; Dearnaley D; Flux G
    Cancer Biother Radiopharm; 2005 Apr; 20(2):189-94. PubMed ID: 15869454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary results of the use of Re-186-HEDP for palliation of pain in patients with metastatic bone disease.
    Giannakenas C; Kalofonos HP; Apostolopoulos DJ; Zarakovitis J; Kosmas C; Vassilakos PJ
    Am J Clin Oncol; 2000 Feb; 23(1):83-8. PubMed ID: 10683086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.